Maropitant

The exact 10 mg/ml dog-and-cat injection has a current transparent EU centrally authorised SPC and active Georgian veterinary registration (251-11).

Maropitant is a well-established NK1 antiemetic with labelled preventive and therapeutic roles across common veterinary nausea and vomiting contexts; it controls the symptom, not the underlying cause.

Usually well tolerated under labelled use, but injection pain, accumulation with repeated dosing and cautions in young, hepatic, cardiac, pregnant or lactating patients require selection and monitoring.

Once-daily SC or IV dosing for up to five days is straightforward in clinic; IV must be a separate bolus and SC discomfort should be anticipated.

The exact 10 mg/ml dog-and-cat injection has a current transparent EU centrally authorised SPC and active Georgian veterinary registration (251-11).

Maropitant reliably reduces feline vomiting and nausea in labelled settings; in CKD it may reduce vomiting without improving appetite or weight, so it is not a substitute for appetite-directed therapy or causal treatment.

Labelled use is generally tolerable, but safety is not established below 16 weeks and hepatic, cardiac, reproductive and repeated-dose cautions are clinically relevant.

Once-daily SC or IV clinic dosing is feasible, but feline restraint, SC pain and the five-day labelled limit can materially affect repeated treatment.

The exact transparent 10 ml dog/cat SC/IV product has a current multi-country EU generic authorisation explicitly linked to Cerenia, a current official product leaflet and Georgian registration. Exact-Bioveta independent outcome or pharmacovigilance data are limited, so reference-product transfer remains visible.

Large multicentre placebo-controlled and European comparative field trials show strong reduction of acute vomiting across diverse canine causes, while label and reference-product evidence support chemotherapy and perioperative roles. It remains symptomatic treatment, excludes injectable motion-sickness use and must not delay diagnosis or source control.

The therapeutic margin is generally good and most adverse effects are local/transient, but SC pain is very common. Hepatic accumulation, cardiac ion-channel caution, protein-binding interactions, age/reproductive uncertainty and rare anaphylactoid or neurologic reactions require selection and monitoring.

Once-daily 0.1 ml/kg dosing, SC/IV choice, 24-hour effect and up-to-five-day course are highly workable in clinic. SC sting, exact undiluted IV bolus/no-mixing instruction, 20-puncture limit and 28-day vial life add manageable route and wastage checks.

The exact transparent 10 ml dog/cat SC/IV product has a current multi-country EU generic authorisation explicitly linked to Cerenia, a current official product leaflet and Georgian registration. Exact-Bioveta independent outcome or pharmacovigilance data are limited, so reference-product transfer remains visible.

Reference-product field data and controlled feline PK/induced-emesis studies strongly support 1 mg/kg SC/IV antiemesis for about 24 hours. Vomiting reduction is consistent, but nausea behaviours may persist despite suppression of emesis and evidence across spontaneous causes is less extensive than in dogs.

Systemic tolerability is generally good, but moderate/severe SC injection reaction occurs in about one third of cats and adult-cat overdose evidence is absent. Hepatic/cardiac caution, age and reproductive limits, interactions and rare anaphylactoid or neurologic reactions remain clinically important.

Once-daily weight-based dosing and an IV option are practical, but marked feline SC pain may require IV access or cooling/restraint and materially affects welfare. The undiluted bolus/no-mixing rule, small-volume accuracy, 20-puncture limit and 28-day vial life need active workflow control.

The exact product is registered in Georgia (000836, valid to 2030) from a Russian state biofactory, and its dose and age limits match the EU-authorised maropitant reference (Cerenia), but no bioequivalence or product data are public and the catalogue source is the maker's home page.

Maropitant at 1 mg/kg is a well-proven NK1-receptor antiemetic in dogs, so the class evidence is strong; equivalence of this formulation to the reference is assumed, not shown.

Maropitant is well tolerated at label dose; the label advises caution in liver disease and heart failure and advises against use in pregnancy or lactation, and subcutaneous injection can sting.

One daily injection of 0.1 ml/kg from a 10 ml vial suits clinic use well, but it stops vomiting without treating its cause.

The exact product is registered in Georgia (000836, valid to 2030) from a Russian state biofactory, and its dose and age limits match the EU-authorised maropitant reference (Cerenia), but no bioequivalence or product data are public and the catalogue source is the maker's home page.

Maropitant at 1 mg/kg is an effective NK1-receptor antiemetic in cats, so the class evidence is strong; equivalence of this formulation to the reference is assumed, not shown.

Maropitant is generally well tolerated in cats at label dose; the label sets a 16-week minimum age and advises caution in liver disease and heart failure, and injection pain is common.

A daily 0.1 ml/kg injection is easy in clinic, though a small cat needs a precisely measured volume and the injection can sting.